Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity

CONCLUSION: These findings suggest that IL-25/IL-17RA may serve as an additional target when treating ICI-responsive tumors, allowing for better tumor control while suppressing immune-related toxicities.PMID:38519059 | DOI:10.1136/jitc-2023-008482

Source: Cancer Control - March 22, 2024 Category: Cancer & Oncology Authors: Xizi Hu Shoiab M Bukhari Carly Tymm Kieran Adam Shalom Lerrer Brian S Henick Robert J Winchester Adam Mor Source Type: research